Metric Finance
LearnFAQ
LearnFAQ

Learn / EDIT

NASDAQ: EDIT

Editas Medicine (EDIT) stock, explained like you're 5

Editas Medicine trades on the Nasdaq under the ticker EDIT. It is a small cap company in the biological products (no diagnostic substances) industry, part of the healthcare sector, with a market value of about 445 million dollars.

Ticker
EDIT
Exchange
Nasdaq
Sector
Healthcare
Industry
Biological Products (No Diagnostic Substances)
Size
Small cap, about 445 million dollars

Is Editas Medicine a small, medium or large cap company?

No. Editas Medicine is a small cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 445 million dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Editas Medicine makes money

  • Selling medicines, medical devices or healthcare services.
  • Insurance premiums or hospital and clinic fees.
  • Research and licensing deals.

What moves EDIT stock

  • Results from clinical trials and approvals from regulators.
  • Drug prices, insurance rules and government policy.
  • Patents running out and new competing treatments.

In the news lately

  • Editas Medicine, Inc. (EDIT) stock price, news, quote and history (Yahoo Finance Australia)
  • Editas Medicine (NASDAQ:EDIT) Stock Breaks Below 50 Day Moving Average Here's Why (MarketBeat)
  • A delivery method generated engineered immune cells inside the body and depleted B cells. (Stock Titan)
  • Editas Medicine (NasdaqGS:EDIT) Stock Forecast & Analyst Predictions (Simply Wall Street)
  • Why is Editas Medicine stock rallying today? (Investing.com)

Follow EDIT in your daily brief

Each trading day at 5 PM ET we post what happened to Editas Medicine and why it matters, in simple words. Free.

Start my free brief

Key terms to know before you follow EDIT

  • Market cap
  • P/E ratio
  • EPS (earnings per share)
  • Earnings report
  • Volatility

Questions about Editas Medicine stock

What does Editas Medicine do?

Editas Medicine trades on the Nasdaq under the ticker EDIT. It is a small cap company in the biological products (no diagnostic substances) industry, part of the healthcare sector, with a market value of about 445 million dollars.

What is the ticker symbol for Editas Medicine?

Editas Medicine trades under the ticker EDIT on the Nasdaq.

What is Editas Medicine's market cap?

Editas Medicine is a small cap stock with a market cap of about 445 million dollars.

How does Editas Medicine make money?

Selling medicines, medical devices or healthcare services. Insurance premiums or hospital and clinic fees. Research and licensing deals.

What moves EDIT stock?

Results from clinical trials and approvals from regulators. Drug prices, insurance rules and government policy. Patents running out and new competing treatments.

How can I follow EDIT stock every day?

Add EDIT to your watchlist on Metric Finance. We post a free brief every trading day at 5 PM ET that explains what happened to the stocks you follow, in simple words.

Follow EDIT daily

A free brief on Editas Medicine and your other stocks, every trading day at 5 PM ET.

Start my free brief

Similar stocks

  • ARGX · Argenx SE
  • RVMD · Revolution Medicines
  • BNTX · BioNTech SE
  • EXEL · Exelixis

Similar stocks

  • ARGXArgenx SE
  • RVMDRevolution Medicines
  • BNTXBioNTech SE
  • EXELExelixis

Compare EDIT: EDIT vs ARGX, EDIT vs RVMD, EDIT vs BNTX

Educational information, not financial advice. This guide explains the business in general terms and does not include live prices.

Metric Finance

Stocks explained like you're 5.

Product

  • Learn
  • FAQ
  • Your account

Legal

  • Privacy
  • Terms

Support

  • Contact
  • Unsubscribe

© 2026 Metric Finance

Built by Yashna & Vansh · Not investment advice · Market data may be delayed